What are the key updates from ESH: 2nd How I manage: CAR T therapies and bispecific antibodies?

During the European Society of Hematology (ESH) 2nd How I manage: CAR-T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to Ulrich Jӓger, Medical University of Vienna, Vienna, AT. We asked, What are the key updates from ESH 2nd How I manage: CAR-T therapies and bispecific antibodies?

Firstly, Jӓger discusses key topics, including the future of chimeric-antigen receptor T-cell therapy and bispecific antibody treatment, the toxicities involved in these treatments, the potential to combine both treatment options, and how to sequence treatments in specific indications. He also highlights key learnings across all indications from the meet-the-expert sessions and debates held at this congress.